Folate receptor (FR) has proven to be a valuable target for chemotherapy using folic acid (FA) conjugates. However, FA-conjugated chemotherapeutics still have low therapeutic efficacy accompanied with side effects, resulting from complications such as short circulation half-life, limited tumor delivery, as well as high kidney accumulation. Herein, we present a novel FA-conjugated paclitaxel (PTX) prodrug which was additionally conjugated with an Evans blue (EB) derivative for albumin binding. The resulting bifunctional prodrug prolonged blood circulation, enhanced tumor accumulation, and consequently improved tumor therapeutic efficacy.
叶酸受体(FR)已被证明是使用叶酸(FA)共轭物进行化疗的重要靶点。然而,FA 结合物化疗药物的疗效仍然很低,同时还伴有副作用,这些副作用是由循环半衰期短、肿瘤给药有限以及肾脏高蓄积等并发症造成的。在本文中,我们介绍了一种新型的 FA 结合物
紫杉醇(
PTX)原药,该原药还与伊文思蓝(EB)衍
生物结合以促进白蛋白结合。由此产生的双功能原药可延长血液循环,增强肿瘤蓄积,从而提高肿瘤疗效。